233 related articles for article (PubMed ID: 33061299)
1. The Activity and Safety of Anlotinib for Patients with Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution.
Zheng C; Zhou Y; Wang Y; Luo Y; Tu C; Min L
Drug Des Devel Ther; 2020; 14():3941-3950. PubMed ID: 33061299
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of apatinib for patients with advanced extremity desmoid fibromatosis: a retrospective study.
Zheng C; Fang J; Wang Y; Zhou Y; Tu C; Min L
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2127-2135. PubMed ID: 33452581
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of anlotinib in patients with desmoid fibromatosis: a retrospective analysis.
Xie M; Huang Q; Gong T; Wang Y; Li Z; Lu M; Luo Y; Min L; Zhou Y; Tu C
Front Oncol; 2024; 14():1399574. PubMed ID: 38807768
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.
Liu Z; Gao S; Zhu L; Wang J; Zhang P; Li P; Zhang F; Yao W
Cancer Med; 2021 Nov; 10(21):7593-7600. PubMed ID: 34564939
[TBL] [Abstract][Full Text] [Related]
5. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
Liu J; Deng YT; Jiang Y
Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefit of methotrexate plus vinorelbine chemotherapy for desmoid fibromatosis (DF) and correlation of treatment response with MRI.
Ingley KM; Burtenshaw SM; Theobalds NC; White LM; Blackstein ME; Gladdy RA; Thipphavong S; Gupta AA
Cancer Med; 2019 Sep; 8(11):5047-5057. PubMed ID: 31301110
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
[TBL] [Abstract][Full Text] [Related]
8. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis.
Zanchetta E; Ciniselli CM; Bardelli A; Colombo C; Stacchiotti S; Baldi GG; Provenzano S; Bertulli R; Bini F; Casale A; Greco FG; Ferrari A; Verderio P; Fiore M; Gronchi A; Casali PG; Morosi C; Palassini E
Cancer Med; 2021 Jul; 10(13):4356-4365. PubMed ID: 34102009
[TBL] [Abstract][Full Text] [Related]
10. Anlotinib treatment in elderly patients with unresectable or metastatic soft tissue sarcoma: a retrospective study.
Zhang XY; Liu J; Deng YT; Jiang Y
Anticancer Drugs; 2022 Jan; 33(1):e519-e524. PubMed ID: 34282747
[TBL] [Abstract][Full Text] [Related]
11. A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer.
Cui Q; Hu Y; Ma D; Liu H
Drug Des Devel Ther; 2021; 15():339-347. PubMed ID: 33536747
[TBL] [Abstract][Full Text] [Related]
12. Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis.
Fiore M; Colombo C; Radaelli S; Callegaro D; Palassini E; Barisella M; Morosi C; Baldi GG; Stacchiotti S; Casali PG; Gronchi A
Eur J Cancer; 2015 Dec; 51(18):2800-7. PubMed ID: 26602014
[TBL] [Abstract][Full Text] [Related]
13. [Long term follow-up results of anlotinib in the treatment of advanced renal cell carcinoma].
Song Y; Yihebali C; Yang L; Cui CX; Zhang W; Sun YK; Du CX; Zhou AP; Wang JW
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):765-770. PubMed ID: 32988160
[No Abstract] [Full Text] [Related]
14. Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose.
Garg V; Gangadharaiah BB; Rastogi S; Upadhyay A; Barwad A; Dhamija E; Gamangatti S
Eur J Cancer; 2023 Jun; 186():142-150. PubMed ID: 37062211
[TBL] [Abstract][Full Text] [Related]
15. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
[TBL] [Abstract][Full Text] [Related]
16. The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial.
Huang NS; Wei WJ; Xiang J; Chen JY; Guan Q; Lu ZW; Ma B; Sun GH; Wang YL; Ji QH; Wang Y
Thyroid; 2021 Dec; 31(12):1808-1813. PubMed ID: 34610756
[No Abstract] [Full Text] [Related]
17. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Zhao Y; Yu H; Zhao Y; Chen W; Luo Y; Wu L; Wang X; Pirker R; Nan K; Jin F; Dong J; Li B; Sun Y
JAMA Oncol; 2018 Nov; 4(11):1569-1575. PubMed ID: 30098152
[TBL] [Abstract][Full Text] [Related]
18. Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib.
Tang M; Song C; Zhang Y; Xu X; Wang C; Zhang Z; Chen T
Lipids Health Dis; 2021 Nov; 20(1):165. PubMed ID: 34801029
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
[TBL] [Abstract][Full Text] [Related]
20. Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of
Mir O; Honoré C; Chamseddine AN; Dômont J; Dumont SN; Cavalcanti A; Faron M; Rimareix F; Haddag-Miliani L; Le Péchoux C; Levy A; Court C; Briand S; Fadel E; Mercier O; Bayle A; Brunet A; Ngo C; Rouleau E; Adam J; Le Cesne A
Clin Cancer Res; 2020 Dec; 26(23):6277-6283. PubMed ID: 32873570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
